Scarica l'app Stockscreener
5.71
1.60%
0.09
Dopo l'orario di chiusura:
5.72
0.010
+0.18%
Precedente Chiudi:
$5.62
Aprire:
$5.64
Volume 24 ore:
451.33K
Relative Volume:
2.00
Capitalizzazione di mercato:
$215.47M
Reddito:
-
Utile/perdita netta:
$-34.55M
Rapporto P/E:
-5.1702
EPS:
-1.1044
Flusso di cassa netto:
$-31.28M
1 W Prestazione:
+17.01%
1M Prestazione:
-4.03%
6M Prestazione:
+74.62%
1 anno Prestazione:
+346.09%
Intervallo 1D:
$5.51
$5.99
Intervallo di 1 settimana:
$4.6701
$5.99
Portata 52W:
$1.00
$7.19
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Nome
An 2 Therapeutics Inc
Settore
Industria
Telefono
(650) 331-9090
Indirizzo
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Compare ANTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
5.71 | 184.15M | 0 | -34.55M | -31.28M | -1.1044 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2024-08-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-12 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Mostra tutto
An 2 Therapeutics Inc Borsa (ANTX) Ultime notizie
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. LawsuitUNCY - PR Newswire
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics - Business Wire
Faruqi & Faruqi, LLP Urges Unicycive Therapeutics, Inc. (UNCY) Investors to Seek Counsel Before the November 2, 2026 Lead Plaintiff Deadline in the Securities Class Action - TMX Newsfile
CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. - GlobeNewswire
UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class ActionContact SueWallSt - PR Newswire
CAPR 2-WEEK DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline - PR Newswire
2 WEEK CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. - GlobeNewswire
Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View - Seeking Alpha
Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress - The Manila Times
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin DeficiencySlideshow (NASDAQ:BEAM) 2026-09-10 - Seeking Alpha
Beam Therapeutics Presents Updated Clinical Data from the - GlobeNewswire
Pretzel Therapeutics Advances PX578 into Phase 2 Study in Individuals Living with POLG-mediated Primary Mitochondrial Disease Following FDA Clearance of IND - Business Wire
HOWL Stock Whipsaws As One-Off Profit Meets Uncertain Future - StocksToTrade
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - GlobeNewswire
Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure - Yahoo Finance
Axsome Therapeutics shares gain 2% as strong sales growth offsets Q2 miss - Yahoo Finance
Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ... - Yahoo Finance
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results - PR Newswire
Akebia Therapeutics Announces Initiation of a Phase 2 - GlobeNewswire
TScan Therapeutics Announces First Patient Dosed in Phase 3 - GlobeNewswire
Cullinan Therapeutics Announces Positive End-of-Phase 1 - GlobeNewswire
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ) - Seeking Alpha
Spyre Therapeutics Inc. (SYRE) Slips 2% as Resistance Holds Firm: Key Levels to WatchDouble Bottom - careplusvn.com
Beam Therapeutics to Present Updated Data from Phase 1/2 - GlobeNewswire
LB Pharmaceuticals Announces Accelerated Timing of Topline - GlobeNewswire
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries - GlobeNewswire
Lupin takes 82.2% stake in Kaveri Therapeutics, licences 2 oncology assets for $1.6mn - The Hindu
4D Molecular Therapeutics (Nasdaq: FDMT) posts positive 2-year wet AMD data - Stock Titan
Diagonal Therapeutics Announces First Patient Dosed in - GlobeNewswire
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) - PR Newswire
Spero Therapeutics and Innovent Biologics Announce - GlobeNewswire
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress - GlobeNewswire
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial - Yahoo Finance
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis - GlobeNewswire
GX-03 Phase 2 signals guide new Stage 2 plan at Turn Therapeutics (NASDAQ: TTRX) - Stock Titan
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of - GlobeNewswire
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - Business Wire
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know - Yahoo Finance
Form 4 Spyre Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Nuo Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 4 Apogee Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Vyne Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Tango Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Lineage Cell Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com - Investing.com UK
Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 4 Oncotelic Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Intellia Therapeutics, Inc. SEC Filing (Jul 2, 2026) | NTLA Form 144 - Stock Titan
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
An 2 Therapeutics Inc Azioni (ANTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
An 2 Therapeutics Inc Azioni (ANTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Readnour Robin Shane | Director |
Sep 08 '26 |
Sale |
6.02 |
10,019 |
60,297 |
557,990 |
| Readnour Robin Shane | Director |
Sep 03 '26 |
Sale |
6.07 |
6,100 |
37,026 |
562,715 |
| Williams Sarah Joanne | Principal Accounting Officer |
Sep 01 '26 |
Sale |
5.53 |
272 |
1,504 |
66,311 |
| FitzPatrick Margaret M | Director |
Sep 01 '26 |
Buy |
5.53 |
2,098 |
11,602 |
10,708 |
| Readnour Robin Shane | Director |
Aug 17 '26 |
Sale |
6.01 |
35,402 |
212,702 |
565,592 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):